- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00433550
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
To assess the confirmed tumor response of the combination of oxaliplatin, irinotecan (irinotecan hydrochloride), and capecitabine in patients with advanced adenocarcinoma of the small bowel when dosed according to UGT1A1 genotype.
SECONDARY OBJECTIVES:
- To assess the toxicity of this regimen in these groups of patients.
- To gain preliminary data on whether microsatellite instability influences outcome within this arm.
- To gain preliminary data on whether evidence of celiac disease may affect toxicity and outcome.
- To gain preliminary data on whether site of tumor origin (duodenal, jejunal, or ileal) affects response or survival.
OUTLINE: Patients are assigned to 1 of 3 treatment groups based on UGT1A1 genotype.
GROUP 1 (6/6 UGT1A1 genotype): Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 2-15.
GROUP 2 (6/7 UGT1A1 genotype): Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
GROUP 3 (7/7 UGT1A1 genotype): Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
In all groups, treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
After the completion of study treatment, patients are followed every 6 weeks for 2 years and then periodically thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
-
-
Iowa
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, United States, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Des Moines, Iowa, United States, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, United States, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, United States, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51102
- Mercy Medical Center - Sioux City
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
-
Kansas
-
Chanute, Kansas, United States, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, United States, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, United States, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, United States, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, United States, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, United States, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, United States, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, United States, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, United States, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, United States, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, United States, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, United States, 67401
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, United States, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, United States, 67214
- CCOP - Wichita
-
Wichita, Kansas, United States, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, United States, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, United States, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Adrian, Michigan, United States, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, United States, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, United States, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, United States, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, United States, 48162
- Mercy Memorial Hospital - Monroe
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Brainerd, Minnesota, United States, 56401
- St. Joseph's Medical Center
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, United States, 55805
- CCOP - Duluth
-
Duluth, Minnesota, United States, 55805
- Miller - Dwan Medical Center
-
Duluth, Minnesota, United States, 55805-1983
- Essentia Health - Duluth Clinic
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, United States, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, United States, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, United States, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology - Maplewood
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, United States, 55422-2900
- Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
Saint Louis Park, Minnesota, United States, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
Shakopee, Minnesota, United States, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Stillwater, Minnesota, United States, 55082
- Lakeview Hospital
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, United States, 56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology - Woodbury
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, United States, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, United States, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, United States, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, United States, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, United States, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, United States, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, United States, 59601
- St. Peter's Hospital
-
Kalispell, Montana, United States, 59901
- Kalispell Regional Medical Center
-
Missoula, Montana, United States, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, United States, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, United States, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, United States, 58502
- St. Alexius Medical Center Cancer Center
-
Grand Forks, North Dakota, United States, 58201
- Altru Cancer Center at Altru Hospital
-
-
Ohio
-
Bowling Green, Ohio, United States, 43402
- Wood County Oncology Center
-
Elyria, Ohio, United States, 44035
- Community Cancer Center
-
Elyria, Ohio, United States, 44035
- Hematology Oncology Center
-
Lima, Ohio, United States, 45804
- Lima Memorial Hospital
-
Maumee, Ohio, United States, 43537-1839
- Northwest Ohio Oncology Center
-
Oregon, Ohio, United States, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, United States, 43616
- Toledo Clinic - Oregon
-
Sylvania, Ohio, United States, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, United States, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Toledo, Ohio, United States, 43623
- St. Anne Mercy Hospital
-
Wauseon, Ohio, United States, 43567
- Fulton County Health Center
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Rapid City Regional Hospital
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, United States, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Manitowoc, Wisconsin, United States, 54221-1450
- Holy Family Memorial Medical Center Cancer Care Center
-
Marinette, Wisconsin, United States, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, United States, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sheboygan, Wisconsin, United States, 53081
- St. Nicholas Hospital
-
Sturgeon Bay, Wisconsin, United States, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Confirmation UDP glucuronosyltransferase 1 family, polypeptide A complex locus (UGT1A1) TA indel genotype of 6/6, 6/7, or 7/7 after pre-registration but prior to registration
- Patient willingness to provide a serum sample for analysis for celiac disease (tissue transglutaminase antibodies)
- Small bowel adenocarcinoma, either metastatic or locally advanced and not surgically resectable; NOTE: periampullary carcinoma and appendiceal cancer are not eligible
- Histologic or cytologic confirmation of adenocarcinoma consistent with small bowel origin; biopsy can be of primary tumor or can be from a metastatic site if there is a primary small bowel tumor currently or previously present
- Measurable disease; for patients with lesions >= 1 cm but < 2 cm, spiral computed tomography (CT) scan imaging must be used for tumor assessments
- Life expectancy >= 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- >= 4 weeks since prior major surgery to time of registration
- >= 2 weeks from completion of any radiation treatment
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- Serum glutamic oxaloacetic transaminase (SGOT) =< 5 x upper normal limit (UNL); =< 2.5 x UNL if no liver metastases
Total bilirubin:
- For 6/6 patients: =< upper limit of normal (ULN)
- For 6/7 or 7/7 patients: =< 2.0 x ULN
- Hemoglobin >= 9.0 g/dL
- Creatinine =< 1.5 x UNL (if > 1.5 x UNL, calculated creatinine clearance should be checked.; if it is > 60 mL/min, then the patient is eligible for the study)
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Exclusion Criteria
- Prior chemotherapy regimen for advanced small bowel cancer (prior adjuvant chemotherapy with fluorouracil (5FU)/leucovorin is permitted if last dose was administered >= 3 months prior to registration); prior oxaliplatin or irinotecan use as adjuvant therapy is not permitted
- Prior radiotherapy to > 25% of bone marrow
- Active or uncontrolled infection
- Evidence of serious intercurrent illness (e.g., unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia)
- Pregnant women; women of child-bearing potential and men must agree to use adequate contraception (diaphragm, birth control pills, injections, foams, intrauterine device [IUD], or abstinence, etc.) for the duration of study participation; if a woman becomes pregnant or suspects that she is pregnant while participating in this study, she should inform her treating physician immediately and all study treatment discontinued
- Nursing women; breast-feeding should be discontinued when the mother is treated with these agents
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Current evidence of other malignancy besides small bowel adenocarcinoma, with exception of non-melanoma skin cancer
- Known central nervous system metastases or carcinomatous meningitis
- Preexisting sensory neuropathy >= grade 2 from any cause interfering with function
- Concurrent therapy with sorivudine, brivudine, lamivudine, or stavudine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (6/6 UGT1A1 genotype)
Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
|
given orally
given IV
given IV
|
Experimental: Group 2 (6/7 UGT1A1 genotype)
Patients receive irinotecan hydrochloride as in group 1.
They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
|
given orally
given IV
given IV
|
Experimental: Group 3 (7/7 UGT1A1 genotype)
Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
|
given orally
given IV
given IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Tumor Response Rate (Proportion of Participants With Complete Response)
Time Frame: 36 weeks
|
Evaluated using RECIST version 1.0.
Confirmed tumor response rate was defined as achieving partial response (PR) or complete response (CR) in two consecutive assessments at least 6 weeks apart.
CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD.
The confirmed response rate is reported as the number of participants with confirmed responses divided by the number of evaluated participants.
|
36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Up to 2 years
|
Overall survival will be defined as the time from registration to death.
Patients lost to follow-up for this endpoint will be censored at the date of last contact (i.e., last known alive).
The distribution of overall survival will be estimated using Kaplan-Meier methodology.
|
Up to 2 years
|
Progression Free Survival
Time Frame: Up to 2 years
|
Time to disease progression is defined as the time from registration to the earlier of documentation of disease progression or death.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
The distribution of time to progression will be estimated using Kaplan-Meier methodology.
|
Up to 2 years
|
Duration of Response
Time Frame: Up to 2 years
|
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.
Duration of response will be analyzed using Kaplan-Meier methods.
|
Up to 2 years
|
Time to Treatment Failure
Time Frame: Up to 2 years
|
Time to treatment failure is defined to be the time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal.
If the patient is considered to have had a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment.
Time to treatment failure will be analyzed using Kaplan-Meier methods.
|
Up to 2 years
|
Collaborators and Investigators
Investigators
- Study Chair: Robert McWilliams, MD, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Adenocarcinoma
- Intestinal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Capecitabine
- Oxaliplatin
- Irinotecan
Other Study ID Numbers
- NCCTG-N0543
- NCI-2009-00650 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000528263 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Small Intestine Cancer
-
Medtronic - MITGRecruitingSmall Intestine Cancer | Small Intestine Adenocarcinoma | Small Intestine Disease | Small Intestinal Ulcer Bleeding | Small Intestine Obstruction | Small Intestine PolypUnited States
-
Medtronic - MITGNot yet recruitingSmall Intestine Cancer | Small Intestine Adenocarcinoma | Small Intestine Disease | Small Intestinal Ulcer Bleeding | Small Intestine Obstruction | Small Intestine Polyp
-
Wageningen UniversityWageningen University and ResearchCompleted
-
Lawson Health Research InstituteCompleted
-
United Lincolnshire Hospitals NHS TrustUnknownSmall Intestine Problem
-
Mayo ClinicIcahn School of Medicine at Mount Sinai; Imperial College London; University... and other collaboratorsCompletedSmall Intestine BacteriaUnited States
-
National Cancer Institute (NCI)TerminatedFallopian Tube Cancer | Small Intestine Lymphoma | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Primary Peritoneal Cavity Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small... and other conditionsUnited States
-
Cedars-Sinai Medical CenterNational Cancer Institute (NCI)RecruitingGastrointestinal Neoplasms | Stomach Cancer | Small Intestine Cancer | Rectal Cancer | Neuroendocrine Tumor | Bile Duct Cancer | Colon Cancer | Pancreas Cancer | Anal Cancer | Liver Cancer | Biliary Tract Cancer | Peritoneal Cancer | Carcinoid Tumor | Gallbladder Cancer | Cancer Pain | Carcinoid Tumor of the Small Bowel | Visceral... and other conditionsUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteInstituto de Salud Carlos IIICompleted
-
Burzynski Research InstituteTerminatedSmall Intestine CancerUnited States
Clinical Trials on capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Hoffmann-La RocheCompletedBreast Cancer, Colorectal CancerNew Zealand, Australia, United Kingdom
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Jules Bordet InstituteCompletedBreast Cancer | Elderly PatientsBelgium
-
Samsung Medical CenterCompletedAdvanced or Recurrent Esophageal Squamous Cell CarcinomaKorea, Republic of
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer